vs
Side-by-side financial comparison of CITIUS ONCOLOGY, INC. (CTOR) and Moolec Science SA (MLEC). Click either name above to swap in a different company.
CITIUS ONCOLOGY, INC. is the larger business by last-quarter revenue ($3.9M vs $2.6M, roughly 1.5× Moolec Science SA). Moolec Science SA runs the higher net margin — -91.8% vs -140.3%, a 48.5% gap on every dollar of revenue.
Citius Oncology, Inc. is a late-stage biopharmaceutical company focused on developing innovative targeted therapies for cancer patients. Its core pipeline covers treatments addressing unmet medical needs in hematologic malignancies and solid tumors, primarily serving North American and global oncology care markets.
Moolec Science SA is a global agricultural biotechnology and food technology company specializing in molecular farming. It uses engineered crop platforms to produce sustainable, cost-competitive animal-derived proteins for use in alternative meat, dairy products and food ingredients, serving food manufacturers, agribusinesses and consumer goods brands across North America, Europe and Latin America.
CTOR vs MLEC — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.9M | $2.6M |
| Net Profit | $-5.5M | $-2.4M |
| Gross Margin | 80.0% | -25.5% |
| Operating Margin | -133.2% | -77.9% |
| Net Margin | -140.3% | -91.8% |
| Revenue YoY | — | — |
| Net Profit YoY | 16.9% | — |
| EPS (diluted) | $-0.06 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.9M | — | ||
| Q4 24 | — | $2.6M | ||
| Q3 23 | — | $1.7M |
| Q4 25 | $-5.5M | — | ||
| Q4 24 | — | $-2.4M | ||
| Q3 23 | — | $-1.6M |
| Q4 25 | 80.0% | — | ||
| Q4 24 | — | -25.5% | ||
| Q3 23 | — | 12.7% |
| Q4 25 | -133.2% | — | ||
| Q4 24 | — | -77.9% | ||
| Q3 23 | — | -130.3% |
| Q4 25 | -140.3% | — | ||
| Q4 24 | — | -91.8% | ||
| Q3 23 | — | -91.4% |
| Q4 25 | $-0.06 | — | ||
| Q4 24 | — | $-0.06 | ||
| Q3 23 | — | $-0.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.3M | $1.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $58.4M | $2.8M |
| Total Assets | $110.0M | $31.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $7.3M | — | ||
| Q4 24 | — | $1.9M | ||
| Q3 23 | — | $853.6K |
| Q4 25 | $58.4M | — | ||
| Q4 24 | — | $2.8M | ||
| Q3 23 | — | $8.9M |
| Q4 25 | $110.0M | — | ||
| Q4 24 | — | $31.4M | ||
| Q3 23 | — | $22.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-7.4M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 4.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-7.4M | — | ||
| Q4 24 | — | — | ||
| Q3 23 | — | $-1.7M |
| Q4 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 23 | — | $-1.8M |
| Q4 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 23 | — | -106.2% |
| Q4 25 | — | — | ||
| Q4 24 | — | 4.4% | ||
| Q3 23 | — | 6.0% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
